Letter to the Editor: Decoding pediatric-adult divergence in inflammatory bowel disease via multi-omics integration

Abstract

The study by Zakharzhevskaya et al illustrates how integrating metabolic and metagenomic approaches can reveal pathophysiological features of inflammatory bowel disease (IBD). Their work identifies distinct microbial and metabolic profiles in pediatric and adult patients, suggesting potential biomarkers for early diagnosis and risk assessment. Importantly, the authors also develop and validate a novel risk prediction algorithm specifically for pediatric IBD. While this multi-omics framework represents a major step forward, using these findings in clinical practice will require a deeper look into the underlying pathways. This letter highlights key methodological limitations in Zakharzhevskaya et al’s study and puts forward a cross-population framework to accelerate the clinical application of age-specific IBD biomarkers. Future studies should focus on single-cell multi-omics, mapping immune-microbiome interactions, and comparing age-related immune responses in IBD to improve the practical value of the research.

Key Words: Inflammatory bowel disease; Metabolomics; Metagenomics; Pediatric patients; Microbial profiling; Single-cell multi-omics

Core Tip: This multi-omics investigation delineates distinct age-specific microbial and metabolic signatures differentiating pediatric and adult inflammatory bowel disease, identifying biomarkers for early diagnosis and risk stratification. While demonstrating promising potential for refining inflammatory bowel disease diagnostics, these findings require further validation and mechanistic exploration to facilitate clinical translation. The integration of metabolomic and metagenomic methodologies provides a robust framework for elucidating pathophysiological divergence across age groups, providing a foundation for personalized management strategies.

TO THE EDITOR

Inflammatory bowel disease (IBD) refers to a complex chronic disorder characterized by evolving epidemiological trends and distinct clinical presentations across different age groups, which primarily includes two types: Ulcerative colitis and Crohn’s disease[1]. Zakharzhevskaya et al[2] recently reported that a combined metabolomic and metagenomic analysis reveals significant diversity in the pathophysiology of IBD between pediatric and adult patients. Distinct clinical progression between pediatric and adult-onset IBD significantly influences disease management, affecting treatment timing, medication selection, and long-term monitoring. The multi-omics study by Zakharzhevskaya et al[2] provides key molecular insights into age-specific mechanisms behind these differences, supporting the design of age-appropriate diagnostic and personalized therapeutic strategies. Understanding these heterogeneities is critical for optimizing pediatric therapies, as early targeted intervention can improve long-term outcomes. The research demonstrates that pediatric IBD patients exhibit distinct metabolic profiles compared to adults, revealing significant alterations in indole, pentanoic acid, and 4-methylphenol levels. Microbial profiling identifies Streptococcus salivarius and Escherichia coli as key biomarkers for pediatric IBD risk, while species-level analysis identifies Ralstonia insidiosa and Blautia spp. as markers for Crohn’s disease. The authors further proposed a metabolic-based risk prediction algorithm for pediatric IBD, suggesting its potential as a non-invasive tool for early diagnosis. These findings highlight the potential of functional metabolomics in enhancing early diagnosis and personalized management strategies for IBD patients[3]. Nevertheless, a deeper mechanistic understanding, particularly regarding the causal relationships between microbial components and metabolites, remains a challenge and a critical direction for future research. The innovative approach of combining real-time metabolomic data with longitudinal microbial profiling represents a significant methodological advancement in the field.

Microbial profiling concerns

The detection of microbial taxa such as Ralstonia insidiosa and Stenotrophomonas maltophilia raises important questions regarding the contamination control in low-biomass samples (e.g., pediatric fecal or mucosal biopsies, which contain relatively low microbial DNA)[4]. Misclassifying contaminants as disease-associated microbiota may lead to the failure of biomarker development. Future studies would benefit from incorporating rigorous negative controls and advanced decontamination protocols to distinguish true microbial signals from technical errors. Such methodological improvements are particularly crucial for validating proposed biomarkers, including Streptococcus salivarius and Escherichia coli as pediatric-specific indicators[5]. Furthermore, adding quantitative microbial load assessments would help distinguish true biological signals from potential contaminants, especially for microbe types that are not very common but might be important in how the disease develops[6].

Age-specific metabolic differences

The distinct metabolic profiles observed between pediatric and adult IBD patients provide evidence for age-related metabolic divergence in disease development. The altered components, such as 1H-indole-3-methyl and pentanoic acid, align with emerging evidence regarding the ontogeny of gut microbiota and host metabolism[7-9]. The observed reduction in the levels of indole may reflect impaired tryptophan metabolism[10], a pathway increasingly recognized for its role in immune regulation through aryl hydrocarbon receptor activation[11]. Further investigation using advanced in vitro models, such as gut-on-a-chip systems or patient-derived organoids, could help elucidate how these metabolic derivatives modulate epithelial barrier function in age-specific contexts[12]. These studies on mechanisms would add to the link-based results and provide a better understanding of how IBD develops. The age-dependent changes in microbial metabolic capacity may reflect fundamental differences in host-microbe interactions, which warrant further exploration through targeted functional studies[13].

Advanced data integration approaches

The correlation analysis between microbial taxa and metabolites establishes a solid foundation for understanding functional interactions within the gut ecosystem. However, employing advanced integration methodologies such as multi-omics factor analysis or network-based modeling could reveal previously unrecognized hubs driving IBD pathogenesis. The inverse relationship observed between Streptococcus salivarius and heptanoic acid in pediatric ulcerative colitis patients particularly needs to be tested in lab experiments to confirm a potential cause-and-effect link. New developments in computational biology, including machine learning for multi-omics data integration, offer promising ways to identify mechanisms of host-microbe interactions in IBD. Furthermore, integrating epigenetic data and host genetic factors can provide deeper insights into the molecular mechanisms underlying age-specific disease pathology. Incorporating epigenetic data (e.g., DNA methylation age markers) may reveal how host regulatory mechanisms interact with microbial metabolites to drive age-specific disease phenotypes, bridging the critical gap from correlation to causal inference.

Prospective research directions

The findings from Zakharzhevskaya et al[2] highlight several promising research directions that merit further investigation. Multi-center validation studies that include geographic and ethnic populations could help address potential confounding factors related to dietary patterns and medication use. Mechanistic investigations using germ-free animal models could provide important insights into causal relationships between identified biomarkers and IBD. Future research could integrate single-cell multi-omics technologies to dissect, at a higher resolution, the interaction between intestinal mucosal immune cells and specific microbial communities during the progression of IBD. Moreover, constructing age-specific immune-microbe interaction maps will help clarify the differences in disease progression and treatment responses between pediatric and adult IBD, and provide novel targets for the development of age-specific immune-regulating therapies. We would welcome opportunities to collaborate on validating these findings in East Asian cohorts, potentially enhancing the global applicability of these important discoveries. Future studies should also consider examining the impact of therapeutic interventions on these metabolic signatures to assess their utility as treatment response biomarkers.

CONCLUSION

The study by Zakharzhevskaya et al[2] represents a significant advancement in our understanding of age-specific pathophysiological mechanisms in IBD through integrated multi-omics approaches. Their work not only identifies distinct alterations in gut microbiome and metabolic profile between pediatric and adult patients but also develops a metabolite-based risk prediction model for pediatric IBD diagnosis. However, mechanistic insights into the proposed pathways and causal links between microbial components and metabolites remain insufficient. Future investigation should focus on elucidating the mechanistic foundations of these biomarkers and exploring their potential as therapeutic targets. By building upon this important work, we can move closer to achieving precision medicine approaches that account for the unique characteristics of IBD in different age groups, ultimately improving patient outcomes through earlier diagnosis and more targeted interventions.